Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Sjogren's Syndrome therapeutics.

Key Highlights

  • In 2022, there will be more than 3.9 million diagnosed prevalence cases of Sjogren’s Syndrome across 16 pharmaceutical markets.
  • No FDA-approved marketed drugs have been available for Sjogren’s Syndrome in the last two decades.
  • The Sjogren’s Syndrome pipeline consists of 49 pharmaceuticals spanning all stages of development, with approximately 36% of drugs in mid- to late-stage development.
  • Commercial sponsors dominate clinical trial development in Sjogren’s Syndrome, with the US emerging as the key countries for conducting trials in Sjogren’s Syndrome.
  • Deals involving partnerships were the most common type of deals globally.
  • Therapeutic options for Sjogren’s Syndrome patients continue to be limited as only two new product approvals are expected within the next 5 years.
Scope

GlobalData’s Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Sjogren's Syndrome market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sjogren's Syndrome market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Report Scope
  • Abbreviations
  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Total Prevalent Cases of SS in 2022
      • Table Epidemiology Overview: Total Prevalent Cases of SS in 2022
  • Treatment Overview
    • Treatment Guidelines
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in SS
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Phase II Pipeline Drugs in SS
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Drug-Specific PTSRs and LoA in SS
      • Table Pipeline Drugs - Drug-Specific PTSRs and LoA in SS
    • Pipeline Drugs - PTSRs and LoA in Immunology and in SS
  • Clinical Trials Assessment
    • Clinical Trials in SS - Historical Overview
    • Clinical Trials in SS - Overview by Phase
    • Clinical Trials in SS - Overview by Status
    • Clinical Trials in SS - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in SS - Trials with a Virtual Component
    • Clinical Trials in SS - Geographic Overview
    • Clinical Trials in SS - Single-Country and Multinational Trials by Region
    • Clinical Trials in SS - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in SS - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in SS - Overview by Endpoint Status
    • Clinical Trials in SS - Overview by Race and Ethnicity
    • Clinical Trials in SS - Enrollment Data
    • Clinical Trials in SS - Overview of Sites by Geography
    • Clinical Trials in SS - Top 20 Countries for Trial Sites
    • Clinical Trials in SS - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
      • Table Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for SS
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in SS by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in SS
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in SS
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in SS
  • Appendix
    • Methodology
    • Methodology - PTSR and LoA Analysis
    • About the Authors
  • Contact Us
    • Contact Us - A Global Network of Offices

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings